CLARENCE, N.Y.--(BUSINESS WIRE)--22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the initial results of an unprecedented number – more than fifteen – independent scientific studies involving the Company’s SPECTRUM® reduced nicotine tobacco cigarettes were presented by independent scientific researchers at the 22nd Annual Meeting of the Society for Research on Nicotine & Tobacco (“SRNT”) held on March 2 – 5, 2016, in Chicago, Illinois. The annual event was highly attended by participants from around the world, including acclaimed university scientists, FDA and other regulators, and industry professionals. The initial results of the independent scientific studies involving the Company’s proprietary reduced nicotine tobacco cigarettes adds to the mounting body of evidence which shows that the Company’s Very Low Nicotine cigarettes reduce cigarette consumption and assist in smoking cessation.
Due to the fact that the results presented at the SRNT Conference are preliminary and not yet published, 22nd Century is not yet able to release or cite specific study data; however, this link from the SRNT.org website is to the summaries of the initial results of all the scientific studies that were presented at the SRNT Annual Meeting, including the studies on the Company’s reduced nicotine tobacco (see abstract numbers: SYM1B, PA17-1, PA22-5, POS1-19, POS1-50, POS1-74, POS1-104, POS1-107, POS1-129, POS1-137, POS1-146, POS1-148, PA8-5, POS2-6, POS4-20, POS4-95).
“There is a mounting body of evidence that demonstrates that 22nd Century’s proprietary Very Low Nicotine cigarettes are a highly useful tool in helping smokers to quit smoking with no withdrawal symptoms and no exposure to new toxicants,” explained Dr. Paul Rushton, 22nd Century’s Vice President of Plant Biotechnology. “As a result of the numerous independent trials that have already been conducted, we believe a national nicotine reduction policy would have broad beneficial effects on health in the U.S.”
Henry Sicignano, III, President and Chief Executive Officer of 22nd Century Group, stated “We are very proud of our mission – to reduce the harm caused by smoking – and we are honored to have so many prestigious independent researchers conducting important studies with our proprietary Very Low Nicotine tobacco. We look forward to working with interested researchers around the world to design and provide the exact types of Very Low Nicotine research cigarettes that they desire to fit their independent research plans. Ultimately, we hope to be able to provide our highly effective and exciting products to consumers in the U.S. as soon as permitted by the appropriate regulators.”
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The Company’s primary mission is to reduce the harm caused by smoking. 22nd Century currently owns or exclusively controls more than 200 issued patents and more than 50 pending patent applications around the world. The Company’s strong IP position led to a licensing agreement with British American Tobacco (“BAT”), the world’s second largest tobacco company. Visit www.xxiicentury.com for more information.
Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release, including but not limited to our future revenue expectations. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2015, filed on February 18, 2016, including the section entitled “Risk Factors,” and our other reports filed with the U.S Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.